Back


10/09/2017
IMCHECK THERAPEUTICS OBTAINS 1M€ FROM BPIFRANCE TO CONTRIBUTE TO THE DEVELOPMENT OF A NOVEL THERAPEUTIC ANTIBODY IN IMMUNO-ONCOLOGY
ImCheck Therapeutics, an emerging biopharmaceutical company developing a new generation of immunomodulatory antibodies against cancer and auto-immune diseases, announces a funding award of €930,000 from Bpifrance to contribute to the advancement of one of its novel immunotherapy program in cancer. [...]




X

X